Literature DB >> 29523631

Update on 18F-Fluciclovine PET for Prostate Cancer Imaging.

Ephraim E Parent1, David M Schuster2.   

Abstract

PET is a functional imaging method that can exploit various aspects of tumor biology to enable greater detection of prostate cancer than can be provided by morphologic imaging alone. Anti-1-amino-3-18F-flurocyclobutane-1-carboxylic acid (18F-fluciclovine) is a nonnaturally occurring amino acid PET radiotracer that was recently approved by the U.S. Food and Drug Administration for detection of suspected recurrent prostate cancer. The tumor-imaging features of this radiotracer mirror the upregulation of transmembrane amino acid transport that occurs in prostate cancer because of increased amino acid metabolism for energy and protein synthesis. This continuing medical education article provides an overview on 18F-fluciclovine PET diagnostic capabilities for primary and metastatic disease, including reviews of published comparisons to conventional imaging and other molecular imaging agents. Additionally, the imaging procedure and image interpretation are detailed, including physiologic and pathologic uptake patterns and pitfalls.
© 2018 by the Society of Nuclear Medicine and Molecular Imaging.

Entities:  

Keywords:  18F-fluciclovine; amino acid; prostate cancer

Mesh:

Substances:

Year:  2018        PMID: 29523631     DOI: 10.2967/jnumed.117.204032

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  23 in total

1.  Imaging and Characterization of Macrophage Distribution in Mouse Models of Human Prostate Cancer.

Authors:  Ben T Copeland; Hassan Shallal; Chentian Shen; Kenneth J Pienta; Catherine A Foss; Martin G Pomper
Journal:  Mol Imaging Biol       Date:  2019-12       Impact factor: 3.488

2.  Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium.

Authors:  Channing J Paller; Emmanuel S Antonarakis; Tomasz M Beer; Hala T Borno; Maria I Carlo; Daniel J George; Julie N Graff; Shilpa Gupta; Elisabeth I Heath; Celestia S Higano; Rana R McKay; Alicia K Morgans; Akash Patnaik; Daniel P Petrylak; Matthew B Rettig; Charles J Ryan; Mary-Ellen Taplin; Young E Whang; Jacob Vinson; Heather H Cheng; Veda N Giri
Journal:  Clin Genitourin Cancer       Date:  2019-04-18       Impact factor: 2.872

3.  Total Body PET: Why, How, What for?

Authors:  Suleman Surti; Austin R Pantel; Joel S Karp
Journal:  IEEE Trans Radiat Plasma Med Sci       Date:  2020-04-03

4.  [18F]Fluciclovine PET/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging-version 1.0.

Authors:  Cristina Nanni; Lucia Zanoni; Tore Bach-Gansmo; Heikki Minn; Frode Willoch; Trond Velde Bogsrud; Ephraim Parent Edward; Bital Savir-Baruch; Eugene Teoh; Fenton Ingram; Stefano Fanti; David M Schuster
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-12-11       Impact factor: 9.236

5.  Feasibility and Initial Results: Fluciclovine Positron Emission Tomography/Ultrasound Fusion Targeted Biopsy of Recurrent Prostate Cancer.

Authors:  Baowei Fei; Olayinka A Abiodun-Ojo; Akinyemi A Akintayo; Oladunni Akin-Akintayo; Funmilayo Tade; Peter T Nieh; Viraj A Master; Mehrdad Alemozaffar; Adeboye O Osunkoya; Mark M Goodman; David M Schuster
Journal:  J Urol       Date:  2019-07-08       Impact factor: 7.450

6.  18F-Fluciclovine versus PSMA PET Imaging in Primary Tumor Detection during Initial Staging of High-Risk Prostate Cancer: A Systematic Review and Meta-Analysis.

Authors:  Divya Yadav; Hyunsoo Hwang; Wei Qiao; Rituraj Upadhyay; Brian F Chapin; Chad Tang; Ana Aparicio; Maria A Lopez-Olivo; Stella K Kang; Homer A Macapinlac; Tharakeswara K Bathala; Devaki Shilpa Surasi
Journal:  Radiol Imaging Cancer       Date:  2022-03

7.  Isolated Hepatic Metastasis of Prostate Cancer with Variable 18F-fluociclovine Uptake by PET/CT Imaging.

Authors:  Endel Sorra; Muhammad U Aziz; Fangyu Peng
Journal:  Nucl Med Mol Imaging       Date:  2019-11-22

8.  Comparing the diagnostic performance of radiotracers in recurrent prostate cancer: a systematic review and network meta-analysis.

Authors:  Ian Leigh Alberts; Svenja Elizabeth Seide; Clemens Mingels; Karl Peter Bohn; Kuangyu Shi; Helle D Zacho; Axel Rominger; Ali Afshar-Oromieh
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-02-06       Impact factor: 9.236

9.  An international expert opinion statement on the utility of PET/MR for imaging of skeletal metastases.

Authors:  Jad S Husseini; Bárbara Juarez Amorim; Angel Torrado-Carvajal; Vinay Prabhu; David Groshar; Lale Umutlu; Ken Herrmann; Lina García Cañamaque; José Ramón García Garzón; William E Palmer; Pedram Heidari; Tiffany Ting-Fang Shih; Jacob Sosna; Cristina Matushita; Juliano Cerci; Marcelo Queiroz; Valdair Francisco Muglia; Marcello H Nogueira-Barbosa; Ronald J H Borra; Thomas C Kwee; Andor W J M Glaudemans; Laura Evangelista; Marco Salvatore; Alberto Cuocolo; Andrea Soricelli; Christian Herold; Andrea Laghi; Marius Mayerhoefer; Umar Mahmood; Ciprian Catana; Heike E Daldrup-Link; Bruce Rosen; Onofrio A Catalano
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-02-22       Impact factor: 9.236

10.  The Diagnostic Role of 18F-Choline, 18F-Fluciclovine and 18F-PSMA PET/CT in the Detection of Prostate Cancer With Biochemical Recurrence: A Meta-Analysis.

Authors:  Rang Wang; Guohua Shen; Mingxing Huang; Rong Tian
Journal:  Front Oncol       Date:  2021-06-17       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.